One To Watch

Napo Pharmaceuticals

Company Overview

A San Francisco-based pharmaceutical subsidiary of Jaguar Health advancing crofelemer, a first-in-class botanical antisecretory agent, toward a mid-2027 NDA filing for ultrarare pediatric intestinal failure disorders. Napo Pharmaceuticals is a wholly owned subsidiary of Nasdaq-listed Jaguar Health, Inc. (JAGX), holding the human health assets around crofelemer. The company has already secured FDA approval for crofelemer as Mytesi, and is now pressing into orphan indications where no approved therapy exists.

Headquarters and Global Presence

Napo is headquartered at 200 Pine Street, Suite 400, San Francisco, CA, co-located with its Jaguar Health parent. Its European rare disease development is handled by Napo Therapeutics S.p.A., a majority owned Italian subsidiary established in Milan in 2021. The pivotal MVID trial runs across the US, EU, and United Arab Emirates, giving the program a genuinely global clinical footprint.

Founding and History

Napo Pharmaceuticals was founded in 2001 by Lisa Conte. Conte also founded Jaguar Animal Health, Inc. in 2013 as the veterinary licensee of Napo's technology, and the two companies merged effective July 31, 2017 to form the combined Jaguar Health, Inc. Since that merger Napo has operated as the private human health subsidiary within the Nasdaq-listed parent, holding the Mytesi label and the rare disease pipeline.

Therapy Areas and Focus

Napo's rare disease focus centers on pediatric microvillus inclusion disease, a congenital enteropathy so severe that affected infants cannot absorb nutrients and require lifelong parenteral support, which itself carries risks including catheter-related infection and liver disease. The second indication, adult short bowel syndrome with intestinal failure, similarly involves parenteral support dependency. Both are underserved by approved pharmacotherapy, which is what makes the orphan drug pathway commercially rational here.

Technology Platforms and Modalities

Crofelemer is derived from sangre de drago, the bark sap of the Croton lechleri tree, an Amazonian species widespread across Peru, Colombia, Ecuador, and Bolivia. The active ingredient is isolated and purified from that latex, making it the first oral botanical prescription drug approved under FDA Botanical Guidance. Mechanistically, crofelemer is a minimally absorbed, locally acting antisecretory agent that inhibits two secretory chloride ion channels in the gastrointestinal tract. That chloride channel mechanism is distinct from opioid-based antidiarrheals and from gut motility agents, and it is the rationale for studying crofelemer in congenital chloride transport disorders.

Key Pipeline and Programs

The lead program is crofelemer powder for oral solution in pediatric microvillus inclusion disease. Napo does not assign a phase number to this study, describing it as a pivotal trial running in the US, EU, and UAE. The randomized double-blind treatment phase was completed as of September 2026, and an NDA submission to the FDA is targeted for mid-2027. Crofelemer holds orphan drug designation for MVID from both the FDA and the European Medicines Agency. Data presented at the ESPGHAN Annual Meeting in June 2026 showed weekly parenteral support normalized to body weight decreased by up to 48% in one MVID patient after more than 12 months of treatment.

The second program is crofelemer powder for oral solution in adult short bowel syndrome with intestinal failure, in a Phase II trial in the EU. Crofelemer also holds orphan drug designation for SBS from both the FDA and the EMA. The ESPGHAN data showed weekly parenteral support decreased by up to 40% in two SBS-IF patients after more than 12 months of treatment.

Separately, Napo Therapeutics S.p.A. has submitted an orphan drug designation application to the EMA for crofelemer in a severe congenital diarrheal disorder, which has not yet been granted. The compassionate use program is active: as of September 4, 2026, an infant with intestinal failure due to congenital sodium diarrhea caused by a GUCY2C gene mutation is receiving crofelemer as adjunctive therapy to reduce parenteral support needs.

The commercial asset, Mytesi (crofelemer delayed-release tablets), received FDA approval on December 31, 2012 for noninfectious diarrhea in adult HIV/AIDS patients on antiretroviral therapy. US commercialization rights were licensed to Woodward Specialty, LLC, an affiliate of Future Pak, effective January 12, 2026.

Recent Developments

The most material development is the completion of the randomized double-blind phase of the pivotal MVID trial, announced September 4, 2026, with an NDA filing targeted for mid-2027. Late-breaking ESPGHAN data from June 2026 showed meaningful reductions in parenteral support burden across both MVID and SBS-IF patients. On the commercial side, the January 2026 licensing agreement with Future Pak, which included a $16 million upfront payment and a $2 million holdback received in August 2026, stripped out US Mytesi revenues but eliminated the associated sales and marketing overhead, freeing resources for the rare disease programs. Jaguar's second quarter 2026 results, reported August 19, 2026, showed R&D spending held at $3.3 million despite total net revenue falling 59% year on year to $1.225 million.

Key Personnel

Lisa Conte serves as Founder, President and Chief Executive Officer of Jaguar Health and is the founder of Napo Pharmaceuticals. Pravin Chaturvedi, PhD, serves as Chief Scientific Officer of both Napo and Jaguar and chairs the Scientific Advisory Board, a role he has held since March 1, 2022; he is the principal scientific voice on the crofelemer rare disease program. Darlene Horton, MD, serves as Chief Medical Officer, and Carol Lizak, MBA, serves as Chief Financial Officer.

Strategic Partnerships

The most consequential recent deal is the US commercial licensing agreement with Woodward Specialty, LLC, an affiliate of Future Pak, signed January 12, 2026, under which Future Pak became exclusive US marketer for Mytesi and Canalevia-CA1. That deal carried a $16 million upfront payment. Napo Therapeutics S.p.A. in Milan handles European development and registration strategy, and has been recognized as Best Pharmaceuticals Innovator of the Year in Europe by The European. Napo also maintains an open investigator-initiated trial program to broaden the crofelemer evidence base.

FAQ Section

The January 2026 licensing deal with Future Pak transferred all US commercial responsibility for Mytesi to a specialist marketer in exchange for a $16 million upfront payment. The trade-off is deliberate: Jaguar's Q2 2026 results showed sales and marketing expense collapsed to $5,000, while R&D spending held at $3.3 million. Napo is concentrating capital on the pivotal MVID program rather than defending market share in a generics-competitive HIV diarrhea indication.

MVID is a congenital enteropathy caused by defects in intestinal epithelial cell architecture, leaving infants unable to absorb nutrients and dependent on lifelong parenteral support. Parenteral support carries its own serious risks, including catheter-related sepsis and liver disease, so any agent that reduces PS burden addresses a clinically significant secondary harm. Crofelemer's inhibitory modulation of secretory chloride ion channels acts directly on the aberrant fluid secretion driving MVID, making the mechanism rationally matched to the pathophysiology.

Crofelemer is not an opioid receptor agonist and is not a gut motility agent. It is a minimally absorbed, locally acting botanical drug that modulates two secretory chloride ion channels in the gastrointestinal epithelium, reducing pathological fluid secretion without systemic exposure. That profile matters in neonatal and pediatric patients, where systemic drug exposure carries disproportionate risk. Its botanical origin from the Croton lechleri tree also made it the first oral botanical prescription drug approved under FDA Botanical Guidance when Mytesi was cleared in 2012.

The randomized double-blind treatment phase of the pivotal trial in pediatric MVID patients was completed as of September 2026, with the study running across US, EU, and UAE sites. Napo has targeted an NDA submission to the FDA for mid-2027. The company has had preliminary FDA discussions about Breakthrough Therapy Designation for MVID and intends to apply if appropriate, though the designation has not been granted. Supporting ESPGHAN data from June 2026 showed up to 48% reduction in weekly parenteral support in a treated MVID patient over more than 12 months.

Napo's rare disease focus covers two pediatric and adult intestinal failure conditions: microvillus inclusion disease and short bowel syndrome with intestinal failure. Both carry orphan drug designation from the FDA and EMA. Through Napo Therapeutics S.p.A. in Milan, the company is also pursuing an EMA orphan designation for a severe congenital diarrheal disorder, and compassionate use has been extended to an infant with congenital sodium diarrhea caused by a GUCY2C gene mutation.

The MVID program is the most advanced, with the pivotal trial's randomized double-blind phase now complete and an NDA targeted for mid-2027. The SBS-IF program is in Phase II in the EU. The mid-2027 NDA filing is the single clearest near-term milestone, and any FDA decision on Breakthrough Therapy Designation would add a further catalyst. The compassionate use cases and ESPGHAN data provide supportive clinical context, but the dataset remains small and open-label outside the pivotal trial.

The key watchpoints are:

Mid-2027 NDA filing for crofelemer in MVID: the pivotal trial's blind phase is complete, but NDA readiness depends on data package assembly and any FDA requests.
Breakthrough Therapy Designation for MVID: preliminary FDA discussions have taken place; a positive decision would accelerate review timelines materially.
Phase II SBS-IF data from the EU: any interim readouts or top-line results from this study will signal the breadth of the rare disease franchise.
Financial sustainability: Jaguar's Q2 2026 net revenue was $1.225 million, down 59%, with R&D running at $3.3 million; the runway to NDA filing is the central financial question.
EMA orphan designation for the congenital diarrheal disorder application, which remains pending.
Compassionate use and investigator-initiated trial data, which could either strengthen or complicate the regulatory narrative ahead of NDA submission.

Want to Update your Company's Profile?